Astria Therapeutics, Inc. (ATXS)
NASDAQ: ATXS · Real-Time Price · USD
6.87
+0.22 (3.31%)
At close: Aug 13, 2025, 4:00 PM
7.00
+0.13 (1.89%)
After-hours: Aug 13, 2025, 5:55 PM EDT
ANSYS Employees
Astria Therapeutics had 78 employees as of December 31, 2024. The number of employees increased by 19 or 32.20% compared to the previous year.
Employees
78
Change (1Y)
19
Growth (1Y)
32.20%
Revenue / Employee
n/a
Profits / Employee
-$1,498,987
Market Cap
387.71M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 78 | 19 | 32.20% |
Dec 31, 2023 | 59 | 17 | 40.48% |
Dec 31, 2022 | 42 | 13 | 44.83% |
Dec 31, 2021 | 29 | 9 | 45.00% |
Dec 31, 2020 | 20 | -7 | -25.93% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
ATXS News
- 1 day ago - Astria Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update - Business Wire
- 7 days ago - Astria Therapeutics Enters into Licensing Agreement with Kaken Pharmaceutical to Develop and Commercialize Navenibart for HAE in Japan - Business Wire
- 9 days ago - Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 5 weeks ago - Astria Therapeutics to Present at Upcoming 2025 US Hereditary Angioedema Association National Summit - Business Wire
- 2 months ago - Astria Therapeutics to Participate in Upcoming Oppenheimer Innovators in Immunology & Inflammation Summit - Business Wire
- 2 months ago - Astria Therapeutics Announces Positive Initial Results from the ALPHA-SOLAR Long-Term Open-Label Trial of Navenibart in Hereditary Angioedema Patients at the European Academy of Allergy and Clinical Immunology Annual Congress - Business Wire
- 2 months ago - Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Annual Congress - Business Wire
- 2 months ago - Astria Therapeutics to Present at Upcoming Jefferies Global Healthcare Conference - Business Wire